Why did PHRX.CN stock spike 50% today?

The 50.00% spike in PHRX.CN stock came on thin volume (2,057 shares) and appears linked to targeted buying after recent R&D and EU distribution updates. Micro-cap healthcare names often move sharply on single announcements.

What is Meyka AI’s rating for PHRX.CN stock?

Meyka AI rates PHRX.CN with a score out of 100 at **67.99 (Grade B)** with a **HOLD** suggestion. The grade reflects benchmark and sector comparisons, financial growth, key metrics and forecast models.

What are realistic short-term price targets for PHRX.CN stock?

A short-term trading reference is **C$0.020** (implied +33.33%). Meyka’s conservative monthly forecast is **C$0.010** (implied -33.33%). Targets depend on clinical news and distribution progress.

What are the main risks to PHRX.CN stock performance?

Key risks for PHRX.CN stock include low liquidity, negative cash flow, regulatory risk for controlled substances, and dependence on successful clinical outcomes and EU distribution.

CA Stocks

PHRX.CN Pharmadrug Inc. (CNQ) up 50% on 23 Feb 2026: What drives the move

ByHuzaifa Zahoor February 23, 2026

PHRX.CN stock rose 50.00% in market hours on 23 Feb 2026, trading at C$0.015 on the TSX Venture (CNQ) in Canada. The move followed a low-volume rally with 2,057 shares changing hands versus a 50-day average of 37,913. Investors flagged recent clinical collaborations and distribution activity in Europe as possible catalysts. We examine price drivers, fundamentals, technicals and what Meyka AI’s grade and forecast mean for short-term trading and longer-term outlook.